Hydroxocobalamin Rph Pharmaceuticals

Hydroxocobalamin, the active ingredient in Hydroxocobalamin Rph Pharmaceuticals, is a Vitamin B12 (cobalamin) presented as an intramuscular injection for intramuscular use. It treats vitamin B12 deficiency, including pernicious anemia, in patients who require supplementation.

GNH USA supplies Hydroxocobalamin Rph Pharmaceuticals as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Hydroxocobalamin is used to correct deficiencies in the vitamin B12 metabolic pathway and associated anemic conditions. - Vitamin B12 deficiency: restores normal B12 levels and improves related hematologic and neurologic signs. - Cobalamin deficiency anemia: supports red blood cell formation and reduces anemia symptoms. - Pernicious anemia: provides the necessary cobalamin when intrinsic factor deficiency prevents oral absorption.

Adverse reactions may occur following intramuscular administration of hydroxocobalamin.

Common Side Effects: - Injection site pain or erythema. - Mild headache. - Transient nausea. - Low‑grade fever. - Dizziness. - Mild fatigue.

Serious or Rare Side Effects: - Anaphylactic reaction. - Severe hypertension. - Thromboembolic events. - Acute hemolysis. - Severe skin rash or Stevens‑Johnson syndrome. - Cardiovascular collapse.

Hydroxocobalamin should be used with attention to patient‑specific factors and handling requirements. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; monitor infant for adverse effects. - Renal impairment: assess renal function before administration. - Known hypersensitivity to cobalamin: avoid use. - Concomitant cyanide poisoning: monitor closely as hydroxocobalamin may be used as an antidote. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydroxocobalamin may interact with certain medications, requiring monitoring.

Major Interactions (Avoid): - Methotrexate: may reduce therapeutic efficacy of methotrexate. - Chloramphenicol: potential antagonism affecting hematologic response. - Anticonvulsants (e.g., phenytoin): may increase metabolism of cobalamin.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect oral B12 absorption, though injectable form less impacted. - Metformin: long‑term use can lower B12 levels; monitor patient status. - Trimethoprim‑sulfamethoxazole: may interfere with cobalamin metabolism.